Merck, Hansoh

Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug
Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound.
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh
Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes a $112 million licensing rights payment for global sales outside China.
Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else
Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.
Merck moves into obesity with deal for Hansoh’s GLP-1 pill
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.
Merck gains rights to Hansoh’s preclinical GLP-1 candidate in deal worth $2bn
Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical GLP-1 candidate in a deal worth over $2bn. The agreement gives Merck a global licence to develop,
Merck Snags Chinese Obesity Drug in Nearly $2 Billion Deal
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
Merck enters $2B licensing deal for weight loss drug
The drug is in preclinical stages and aims to target cardiometabolic benefits, including weight reduction, according to a Dec. 18 news release from Merck. Under the agreement, Merck will have exclusive rights to develop,
Yahoo Finance3d
MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset
Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral ...
FierceBiotech4d
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...
STAT4d
Pharmalittle: We’re reading about a Merck deal for an obesity pill, a departing FDA official, and more
Merck signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's oral obesity drug ...
BioSpace4d
Merck Joins Obesity Pill Race With Up to $2B Hansoh Deal
The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk ...
FiercePharma2d
Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod
Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...
Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For HS-10535
(RTTNews) - Merck & Co., Inc. (MRK), Wednesday announced that the company has entered into an exclusive global license deal with China-based Hansoh Pharma to develop, manufacture and commercialize ...
Why Viking Therapeutics Tumbled by More Than 10% This Week
According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period ...